← Back to Deal Tracker
↗InvestmentVerified
BVF Partners
↓
Superluminal Medicines

Deal Value

Undisclosed

Announced

Thursday, September 3, 2026

Deal Details

Superluminal Medicines raised a $60 million Series B to advance AI- and ML-driven GPCR drug discovery, including a lead obesity program entering Phase 1.

A financial investment providing capital in exchange for equity or strategic partnership.

Related News

Superluminal Medicines raises $60M Series B for AI driven obesity drugs

On September 3, 2026 Superluminal Medicines announced a $60 million oversubscribed Series B round led by BVF Partners to advance its AI- and ML-enabled GPCR drug discovery platform. The Boston biotech plans to fund a Phase 1 trial for a rare genetic obesity program and expand its GPCR pipeline.

Sep 3, 2026

Related Analysis

Technology

Anthropic Built a Wet Lab. The Bottleneck in AI Drug Discovery Was Never the Model.

In one week a frontier lab confirmed it runs physical experiments, Washington put money behind AI replacing animal tests, and a ByteDance spin-off raised $290 million. All three are bets on verification, and that changes how to judge an AI biology company.

View Original Source↗
More Investment DealsBVF Partners DealsSuperluminal Medicines Deals

Related Deals

↗Investment

Unknown → Sarvam AI

UndisclosedOct 13, 2026
↗Investment

Shanghai State Investment Pilot Fund → Pongbot

UndisclosedOct 11, 2026
↗Investment

Uncork Capital → Phinity Labs

UndisclosedOct 11, 2026
↗Investment

Vine Ventures → Persona

UndisclosedOct 10, 2026
↗Investment

Khosla Ventures → TypeSafe AI

UndisclosedOct 10, 2026
↗Investment

Andreessen Horowitz → TypeSafe AI

UndisclosedOct 9, 2026